ftzy.com.cn (PTHL): Debt to Book Capitalization Ratio

Corporate company logo of Pheton Holdings (PTHL)

Pheton Holdings Ltd lacks pricing power as it implements brachytherapy software in PRC hospitals during the pilot phase. The company's technologies provide targeted tumor irradiation while protecting healthy tissues. The SaaS development model ensures high distribution margins. The current debt-to-equity ratio reflects borrowing dynamics, with the indicator reaching the level of 0.03.

PTHL Pheton Holdings: Debt to Book Value in the range 09/06/2024 - 01/16/2026
Manufactured products of Pheton Holdings

Pheton Holdings Ltd (PTHL) is strengthening its position in the Asian healthcare IT and pharmaceutical sector. This ratio compares total liabilities to equity, quantifying the financial stability of the expansion. The metric measures insolvency risk, determining the balance between aggressive growth and debt security. A decrease in this indicator minimizes the probability of bankruptcy but may slow the pace of innovation. By analyzing the company's debt load relative to its balance sheet equity, an investor assesses the efficiency of its leveraged financing management.

Competing companies

Debts to Book Capitalization HLN (Haleon plc)|Debts to Book Capitalization kenvue.com KVUE|VRNA - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio MENS (Jyong Biotech Limited)|Ligand Pharma (LGND) - Debt to Book Capitalization Ratio|Debt to Book Value Amneal Corp|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com|Debt to Book Value LQDA (Liquidia)|GLPG (Galapagos N.V.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ANI Pharma ANIP|Afrezza (MNKD) - Debts to Book Value|AMPH: Debt to Book Value|pacira.com - Debt to Book Capital|SPRY: Debts to Book Capitalization|Theravance Biopharma Inc - Debt to Net Assets Ratio|AQST (Aquestive Pharma) - Debts to Book Capitalization|Debts to Book Value scPharma SCPH|Debt to Book Capitalization Ratio Tectonic Therapeutic, Inc. (TECX)|TNXP (tonixpharma.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio China SXT Pharmaceuticals, Inc. SXTC|EPRX (Eupraxia Pharmaceuticals, Inc.) - Debts to Book Capitalization Ratio|BioHarvest - Debts to Book Capitalization|Debt to Net Assets Ratio EXOZ (Invizyne)|ORMP: Debts to Book Capitalization|Debts to Book Value Entera Bio (ENTX)|Debt to Book Value HYFT|ABVC (ABVC BioPharma Inc.) - Debt to Book Capital|Debt to Book Capitalization Ratio Cumberland Pharma (CPIX)|QNTM - Debts to Book Value|Debt to Book Capitalization Ratio FibroGen, Inc. FGEN|TELO: Debt to Book Value Ratio|RANI: Debt to Book Value|Debt to Net Assets Ratio SNYR (Synergy CHC Corp)|RLYB: Debts to Book Capitalization|Lexaria Bioscience Corp. - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Pulmatrix, Inc.|Debts to Book Value Aptorum APM|Debt to Book Capitalization Ratio Lyra Therapeutics (LYRA)|Debt to Book Capitalization Ratio IBO (Impact BioMedical, Inc.)|Debts to Book Capitalization TNFA (TNF Pharmaceuticals, Inc.)|YCBD: Debt to Book Value Ratio|PainReform Ltd. - Debts to Book Capitalization|Debts to Net Assets Altamira Therapeutics CYTO|Lipella Pharmaceuticals, Inc. (LIPO) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio OPTN|PIRS (Pieris) - Debts to Book Capitalization|PROC - Debt to Net Assets|Debt to Book Capitalization Ratio Petros Pharmaceuticals (PTPI)|Debts to Net Assets qlsyy.net|ACELYRIN - Debt to Book Value|Debt to Net Assets Ratio TFFP